Drug susceptibility distributions in slowly growing non-tuberculous mycobacteria using MGIT 960 TB eXiST

International Journal of Medical Microbiology

Volumn 303, Issue 5, 2013, Pages 270-276

  Hombach, Michael ^a   Somoskövi, Akos ^a   Hömke, Rico ^a   Ritter, Claudia ^a   Böttger, Erik C ^a  

^a UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

ECOFF; M. Avium; M. Intracellulare; M. Kansasii; Susceptibility testing; Therapy

Indexed keywords

AMIKACIN; ANTIBIOTIC AGENT; BACTERIAL RNA; CLARITHROMYCIN; ETHAMBUTOL; MOXIFLOXACIN; OFLOXACIN; RIFABUTIN; RIFAMPICIN; RNA 16S;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM; MYCOBACTERIUM AVIUM; MYCOBACTERIUM INTRACELLULARE; MYCOBACTERIUM KANSASII; NONHUMAN; RNA SEQUENCE; WILD TYPE;

EID: 84891373573     PISSN: 14384221     EISSN: 16180607     Source Type: Journal    
DOI: 10.1016/j.ijmm.2013.04.003     Document Type: Article

References (29)

1. Alcaide, F., Calatayud, L., Santin, M., Martin, R., 2004. Comparative in vitro activities of linezolid, telithromycin, clarithromycin, levofloxacin, moxifloxacin, and four conventional antimycobacterial drugs against Mycobacterium kansasii. Antimicrob. Agents Chemother. 48, 4562-4565.
2. Brown-Elliott, B.A., Nash, K.A., Wallace Jr., R.J., 2012. Antimicrobial susceptibility testing, drug resistance mechanisms, and therapy of infections with nontuberculous mycobacteria. Clin. Microbiol. Rev. 25, 545-582.
3. Brown, B.A., Wallace Jr., R.J., Onyi, G.O., 1992. Activities of clarithromycin against eight slowly growing species of nontuberculous mycobacteria, determined by using a broth microdilution MIC system. Antimicrob. Agents Chemother. 36, 1987-1990.
4. Clinical and Laboratory Standards Institute (CLSI), 2011. Susceptibility Testing of Mycobacteria, Nocardia, and Other Aerobic Actinomycetes: Approved standard M24-A2. CLSI, Wayne, PA.
5. Cremades, R., Rodriguez, J.C., Garcia-Pachon, E., Galiana, A., Ruiz-Garcia, M., Lopez, P., Royo, G., 2011. Comparison of the bactericidal activity of various fluoroquinolones against Mycobacterium tuberculosis in an in vitro experimental model. J. Antimicrob. Chemother. 66, 2281-2283.
6. da Silva Telles, M.A., Chimara, E., Ferrazoli, L., Riley, L.W., 2005. Mycobacterium kansasii: antibiotic susceptibility and PCR-restriction analysis of clinical isolates. J. Med. Microbiol. 54, 975-979.
7. Deshpande, D., Srivastava, S., Meek, C., Leff, R., Gumbo, T., 2010. Ethambutol optimal clinical dose and susceptibility breakpoint identification by use of a novel pharmacokinetic-pharmacodynamic model of disseminated intracellular Mycobacterium avium. Antimicrob. Agents Chemother. 54, 1728-1733.
8. Esteban, J., Ortiz-Perez, A., 2009. Current treatment of atypical mycobacteriosis. Expert Opin. Pharmacother. 10, 2787-2799.
9. Field, S.K., Fisher, D., Cowie, R.L., 2004. Mycobacterium avium complex pulmonary disease in patients without HIV infection. Chest 126, 566-581.
10. Griffith, D.E., Aksamit, T., Brown-Elliott, B.A., Catanzaro, A., Daley, C., Gordin, F., Holland, S.M., Horsburgh, R., Huitt, G., Iademarco, M.F., Iseman, M., Olivier, K., Ruoss, S., von Reyn, C.F., Wallace Jr., R.J., Winthrop, K., 2007. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am. J. Respir. Crit. Care Med. 175, 367-416.
11. Guna, R., Munoz, C., Dominguez, V., Garcia-Garcia, A., Galvez, J., de Julian-Ortiz, J.V., Borras, R., 2005. In vitro activity of linezolid, clarithromycin and moxifloxacin against clinical isolates of Mycobacterium kansasii. J. Antimicrob. Chemother. 55, 950-953.
12. Heifets, L.B., Iseman, M.D., Lindholm-Levy, P.J., 1986. Ethambutol MICs and MBCs for Mycobacterium avium complex and Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 30, 927-932.
13. Kasperbauer, S.H., Daley, C.L., 2008. Diagnosis and treatment of infections due to Mycobacterium avium complex. Semin. Respir. Crit. Care Med. 29, 569-576.
14. Kobashi, Y., Yoshida, K., Miyashita, N., Niki, Y., Oka, M., 2006. Relationship between clinical efficacy of treatment of pulmonary Mycobacterium avium complex disease and drug-sensitivity testing of Mycobacterium avium complex isolates. J. Infect. Chemother. 12, 195-202.
15. Kunin, C.M., 1996. Antimicrobial activity of rifabutin. Clin. Infect. Dis. 22 (Suppl. 1), S3-S13.
16. Lucke, K., Hombach, M., Friedel, U., Ritter, C., Bottger, E.C., 2012. Automated quantitative drug susceptibility testing of non-tuberculous mycobacteria using MGIT 960/EpiCenter TB eXiST. J. Antimicrob. Chemother. 67, 154-158.
17. Meier, A., Kirschner, P., Springer, B., Steingrube, V.A., Brown, B.A., Wallace Jr., R.J., Bottger, E.C., 1994. Identification of mutations in 23S rRNA gene of clarithromycin-resistant Mycobacterium intracellulare. Antimicrob. Agents Chemother. 38, 381-384.
18. Rodriguez Diaz, J.C., Lopez, M., Ruiz, M., Royo, G., 2003. In vitro activity of new fluoroquinolones and linezolid against non-tuberculous mycobacteria. Int. J. Antimicrob. Agents 21, 585-588.
19. Rogall, T., Flohr, T., Bottger, E.C., 1990. Differentiation of Mycobacterium species by direct sequencing of amplified DNA. J. Gen. Microbiol. 136, 1915-1920.
20. Sison, J.P., Yao, Y., Kemper, C.A., Hamilton, J.R., Brummer, E., Stevens, D.A., Deresinski, S.C., 1996. Treatment of Mycobacterium avium complex infection: do the results of in vitro susceptibility tests predict therapeutic outcome in humans? J. Infect. Dis. 173, 677-683.
21. Springer, B., Lucke, K., Calligaris-Maibach, R., Ritter, C., Bottger, E.C., 2009. Quantitative drug susceptibility testing of Mycobacterium tuberculosis by use of MGIT 960 and EpiCenter instrumentation. J. Clin. Microbiol. 47, 1773-1780.
22. Subcommittee of the Joint Tuberculosis Committee of the British Thoracic Society, 1999. Management of opportunist mycobacterial infections: Joint Tuberculosis Committee guidelines 1999. Thorax 55, 210-218.
23. Sulochana, S., Rahman, F., Paramasivan, C.N., 2005. In vitro activity of fluoroquinolones against Mycobacterium tuberculosis. J. Chemother. 17, 169-173.
24. Telenti, A., Marchesi, F., Balz, M., Bally, F., Bottger, E.C., Bodmer, T., 1993. Rapid identification of mycobacteria to the species level by polymerase chain reaction and restriction enzyme analysis. J. Clin. Microbiol. 31, 175-178.
25. Turnidge, J., Paterson, D.L., 2007. Setting and revising antibacterial susceptibility breakpoints. Clin. Microbiol. Rev. 20, 391-408.
26. van Ingen, J., van der Laan, T., Dekhuijzen, R., Boeree, M., van Soolingen, D., 2010. In vitro drug susceptibility of 2275 clinical non-tuberculous Mycobacterium isolates of 49 species in The Netherlands. Int J. Antimicrob. Agents 35, 169-173.
27. van Ingen, J., Boeree, M.J., van Soolingen, D., Mouton, J.W., 2012a. Resistance mechanisms and drug susceptibility testing of nontuberculous mycobacteria. Drug Resist. Updat. 15, 149-161.
28. van Ingen, J., Egelund, E.F., Levin, A., Totten, S.E., Boeree, M.J., Mouton, J.W., Aarnoutse, R.E., Heifets, L.B., Peloquin, C.A., Daley, C.L., 2012b. The pharmacokinetics and pharmacodynamics of pulmonary Mycobacterium avium complex disease treatment. Am. J. Respir. Crit. Care Med. 186, 559-565.
29. Yang, B., Koga, H., Ohno, H., Ogawa, K., Fukuda, M., Hirakata, Y., Maesaki, S., Tomono, K., Tashiro, T., Kohno, S., 1998. Relationship between antimycobacterial activities of rifampicin, rifabutin and KRM-1648 and rpoB mutations of Mycobacterium tuberculosis. J. Antimicrob. Chemother. 42, 621-628.